Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.

中文翻译：

---

在美国停止肺动脉高压治疗的相关因素

有关导致肺动脉高压（PAH）治疗中断的因素的信息有限。这项研究分析了 12,902 名新的 PAH 药物使用者，以确定停止治疗的预测因素。由经认可的肺动脉高压中心进行的治疗以及与不同类别的 PAH 药物的联合治疗不太可能导致停药。